Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype

Modern Pathology

Volumn 29, Issue 9, 2016, Pages 1028-1037

  Kostine, Marie ^a,b   Cleven, Arjen H G ^a   De Miranda, Noel F C C ^a   Italiano, Antoine ^c   Cleton Jansen, Anne Marie ^a   Bovée, Judith V M G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HÔPITAL PELLEGRIN   (France)

^c INSTITUT BERGONIÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HLA ANTIGEN CLASS 1; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; HLA ANTIGEN; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARTILAGE TUMOR; CELL DEDIFFERENTIATION; CENTRAL CHONDROSARCOMA; CHONDROSARCOMA; CONTROLLED STUDY; DEDIFFERENTIATED CHONDROSARCOMA; DRUG RESPONSE; ELECTRIC POTENTIAL; ENCHONDROMA; HLA SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAJOR CLINICAL STUDY; MESENCHYMAL CHONDROSARCOMA; MESENCHYME CELL; OSTEOCHONDROMA; OSTEOSARCOMA; OVERALL SURVIVAL; PERIPHERAL CHONDROSARCOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T LYMPHOCYTE; TISSUE MICROARRAY; TISSUE SECTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; BONE TUMOR; CLINICAL TRIAL; EUROPE; IMMUNOLOGY; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; PATHOLOGY; PATIENT SELECTION; PROCEDURES;

B7-H1 ANTIGEN; BIOMARKERS, TUMOR; BONE NEOPLASMS; CELL DEDIFFERENTIATION; CHONDROSARCOMA; EUROPE; HLA ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; T-LYMPHOCYTES; TISSUE ARRAY ANALYSIS;

EID: 84975132631     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.108     Document Type: Article

References (41)

1. Hogendoorn PC, Bovée JV, Nielsen GP, et al. Chondrosarcoma (grade I-III), including primary and secondary variants and periosteal chondrosarcoma, dedifferentiated chondrosarcoma, mesenchymal chondrosarcoma and clear cell chondrosarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PC, et al (eds). WHO Classification of Tumours of Soft Tissue and Bone. 4th edn. IARC Press: Lyon, France, 2013, pp 264-274.
2. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol 2011;224: 334-343.
3. Bovée JV, Hogendoorn PC, Wunder JS, et al. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer 2010;10:481-488.
4. Gelderblom H, Hogendoorn PC, Dijkstra SD, et al. The clinical approach towards chondrosarcoma. Oncologist 2008;13:320-329.
5. Meijer D, de Jong D, Pansuriya TC, et al. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes Cancer 2012;51:899-909.
6. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
7. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375-384.
8. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372:2521-2532.
9. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-smallcell lung cancer. N Engl J Med 2015;373:1627-1639.
10. Lim J, Poulin NM, Nielsen TO. New strategies in sarcoma: linking genomic and immunotherapy approaches to molecular subtype. Clin Cancer Res 2015;21:4753-4759.
11. Kim C, Kim EK, Han JW, et al. Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma (ASCO Meeting 2015). J Clin Oncol 2015;33 (Suppl; abstr 10565).
12. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015;27:450-461.
13. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-2199.
14. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-128.
15. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-571.
16. Tarpey PS, Behjati S, Cooke SL, et al. Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma. Nat Genet 2013;45:923-926.
17. Meng X, Huang Z, Teng F, et al. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev 2015;41:868-876.
18. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320-330.
19. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-2028.
20. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2015;387:1540-1550.
21. Garrido F, Aptsiauri N, Doorduijn EM, et al. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol 2016;39: 44-51.
22. van Oosterwijk JG, van Ruler MA, Briaire-de Bruijn IH, et al. Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells. Br J Cancer 2013;109:1214-1222.
23. van Oosterwijk JG, Meijer D, van Ruler MA, et al. Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets. Am J Pathol 2013;182:1347-1356.
24. Baranski Z, Booij TH, Cleton-Jansen AM, et al. Avenmediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma. J Pathol 2015;236:348-359.
25. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-213.
26. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 2011;9:216.
27. Sarcoma Alliance for Research through Collaboration. SARC028: A phase II study of the anti-PD1 antibody Pembrolizumab (MK-3475) in patients with advanced sarcomas. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2016 Feb 25]. Available from: http://clinicaltrials.gov/ show/NCT02301039.
28. Bovée JV, Cleton-Jansen AM, Rosenberg C, et al. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol 1999;189:454-462.
29. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348:69-74.
30. Lussier DM, Johnson JL, Hingorani P, et al. Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer 2015;3:21.
31. Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014;512:324-327.
32. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127-137.
33. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12: 252-264.
34. Campoli M, Ferrone S. HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Semin Immunopathol 2011;33: 321-334.
35. Nota S, Sabbatino F, Nielsen P, et al. Human Leukocyte Antigen (HLA) Expression and Immunological Events in Chondrosarcoma. In: International Society of Limb Salvage (ISOLS) and Musculoskeletal Tumor Society (MSTS) annual meeting; 2015 Oct 6-10; Orlando. Rosemont (IL): ISOLS-MSTS; 2015. Abstract no. 11468.
36. Bluman EM, Coulie PG, Xiaojuan S, et al. Lysis of human chondrosarcoma cells by cytolytic T lymphocytes recognizing a MAGE-A3 antigen presented by HLA-A1 molecules. J Orthop Res 2007;25:678-684.
37. Pollack SM, Li Y, Blaisdell MJ, et al. NYESO-1/ LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5- Aza-2-deoxycitabine. PLoS One 2012;7:e32165.
38. Endo M, de Graaff MA, Ingram DR, et al. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. Mod Pathol 2015;28:587-595.
39. Kim JR, Moon YJ, Kwon KS, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One 2013;8:e82870.
40. D'Angelo SP, Shoushtari AN, Agaram NP, et al. Prevalence of tumour-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol 2015;46:357-365.
41. Lussier DM, O'Neill L, Nieves LM, et al. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother 2015;38:96-106.